Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

52.44 -0.75 (-1.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks ↗
The company paused a study of a cystic fibrosis treatment, right on the heels of a scrapped type 1 diabetes program. 
Via Investor's Business Daily
Topics Government Intellectual Property
News headline image
Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant ↗
On Wednesday, April 30, 2025, Cathie Wood sold $2.65 million worth of Palantir shares through various ARK ETFs. 
Via Benzinga
News headline image
2 Beaten-Down Stocks With Incredible Upside Potential ↗
Via The Motley Fool
News headline image
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why ↗
Via The Motley Fool
News headline image
Market Whales and Their Recent Bets on CRSP Options ↗
 
Via Benzinga
News headline image
5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years ↗
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
3 Magnificent Stocks That Could Double or More by 2030 ↗
Via The Motley Fool
News headline image
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗
Via The Motley Fool
News headline image
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street ↗
Via The Motley Fool
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The iconic growth investor made some interesting moves during Friday's market pullback. 
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox ↗
 
Via Benzinga
News headline image
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March ↗
Via The Motley Fool
Topics Bankruptcy Economy World Trade
News headline image
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗
Via The Motley Fool
Topics Government World Trade
News headline image
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies. 
Via Investor's Business Daily
News headline image
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
2 Beaten-Down Stocks to Buy on the Dip ↗
Via The Motley Fool
News headline image
2 No-Brainer Biotech Stocks to Buy Right Now ↗
Via The Motley Fool
News headline image
Cathie Wood Stands By Tesla's $2,600 Price Target Despite 40% Stock Drop: 'It's Winner Take Most ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Continues To Load Up On Tempus AI, Dumps Bitcoin-Focused Block In Tech Meltdown Aftermath ↗
On Tuesday, Cathie Wood‘s Ark Invest executed notable trades, including significant activity involving Tempus AI Inc. (NASDAQ:TEM), Block Inc. (NYSE:XYZ), and DraftKings Inc.< 
Via Benzinga
Topics Artificial Intelligence
News headline image
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. ↗
Via The Motley Fool
News headline image
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street ↗
Via The Motley Fool
News headline image
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
News headline image
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
 
Via Benzinga
News headline image
This Informatica Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
The Ultimate Healthcare Stock to Buy With $500 Right Now ↗
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday ↗
Via The Motley Fool
News headline image
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.